+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer



Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer



Bmc Cancer 16: 109



The bone scan index (BSI), which is obtained using a computer-aided bone scan evaluation system, is anticipated to become an objective and quantitative clinical tool for evaluating bone metastases in prostate cancer. Here, we assessed the usefulness of the BSI as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated using docetaxel. We analyzed 41 patients who received docetaxel for mCRPC. The Bonenavi system was used as the calculation program for the BSI. The utility of the BSI as a predictor of overall survival (OS) after docetaxel was evaluated. The Cox proportional hazards model was used to investigate the association between clinical variables obtained at docetaxel treatment, namely PSA, patient age, liver metastasis, local therapy, hemoglobin (Hb), lactase dehydrogenase (LDH), albumin (Alb), PSA doubling time, and BSI and OS. The median OS after docetaxel therapy was 17.7 months. Death occurred in 22 (53.7%) patients; all deaths were caused by prostate cancer. In multivariate analysis, three factors were identified as significant independent prognostic biomarkers for OS after docetaxel; these were liver metastases (yes vs no; HR, 3.681; p = 0.026), Alb (<3.9 vs ≥ 3.9; HR, 3.776; p = 0.020), and BSI (>1% vs ≤ 1%; HR, 3.356; p = 0.037). We evaluated the discriminatory ability of our models including or excluding the BSI by quantifying the c-index. The BSI improved the c-index from 0.758 to 0.769 for OS after docetaxel. CRPC patients with a BSI >1 had a significantly shorter OS than patients with a BSI ≤ 1 (p = 0.029). The BSI, liver metastases and Alb were independent prognostic factors for OS after docetaxel. The BSI might be a useful tool for risk stratification of mCRPC patients undergoing docetaxel treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637593

Download citation: RISBibTeXText

PMID: 26883015

DOI: 10.1186/s12885-016-2160-1


Related references

Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. Bmc Cancer 16: 128, 2016

Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clinical Genitourinary Cancer 11(4): 423-430, 2014

The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. Oncotarget 8(33): 55374-55383, 2017

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian Journal of Andrology 15(1): 110-115, 2013

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of Oncology 27(3): 454-460, 2016

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel. Bmc Cancer 18(1): 501, 2018

Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. Clinical Advances in Hematology and Oncology 13(5): 293-298, 2016

Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clinical Genitourinary Cancer 13(1): 22-31, 2015

Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer. Clinical Advances in Hematology and Oncology 13(5): 293-295, 2016

Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. Clinical Genitourinary Cancer 15(4): 472-478, 2017

Analysis of prognostic factor in 52 castration-resistant prostate cancer treated with docetaxel. Hinyokika Kiyo. Acta Urologica Japonica 58(1): 7-11, 2012

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. Journal of Clinical Oncology 2018: Jco1801279-Jco1801279, 2018

Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 15(1): 53-59, 2016

The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. Anticancer Research 35(5): 3075-3079, 2015

Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. Prostate International 7(1): 9-14, 2019